Publications (120)

2022

  1. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 719-726

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain

    Neurology and Therapy, Vol. 11, Núm. 3, pp. 1183-1192

2020

  1. Acetate correlates with disability and immune response in multiple sclerosis

    PeerJ, Vol. 8

2019

  1. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

  2. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

2017

  1. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

  2. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  3. Multimarker risk stratification approach at multiple sclerosis onset

    Clinical Immunology, Vol. 181, pp. 43-50

2016

  1. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

  2. Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score

    Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150

  3. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

    European Journal of Neurology, Vol. 23, Núm. 1, pp. 182-189

  4. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8

  5. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  6. A consensus initiative for the assessment of patients newly diagnosed with multiple sclerosis in Spain: the eXamina Project

    Neurodegenerative disease management, Vol. 6, Núm. 5, pp. 363-374

2015

  1. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e147

  2. Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

    Neurologia, Vol. 30, Núm. 5, pp. 302-314

  3. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  4. A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1104-1111

  5. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis

    Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627